Aspen Pharmacare in US$308.5m value boost as it joins Johnson & Johnson in Covid-19 vaccine drive

SOUTH AFRICA – Aspen Pharmacare Holdings has added nearly US$ 308.5m to its value after the South African pharmaceutical company said it had invested millions of dollars to manufacture the investigational Covid-19 vaccine with US giant Johnson & Johnson. Aspen through its wholly-owned South African subsidiary, Aspen Pharmacare, had entered into a preliminary agreement with Janssen Pharmaceuticals Inc and Janssen Pharmaceutica NV – two of the Janssen Pharmaceutical companies of Johnson & Johnson – for the technical transfer and proposed commercial manufacture of their Covid-19 vaccine candidate, Ad26.CoV2-S. The vaccine…

Read More

South Africa’s Aspen to sell Japanese business to Novartis for US$442m

SOUTH AFRICA – Aspen Pharmacare Holdings, a global multinational specialty and branded pharmaceutical company, is set to sell its Japanese operations and related intellectual property to Sandoz, a Novartis division, for US$442m (ZAR6.5 billion). The disposal is anticipated to complete in the first half of calendar year 2020. Aspen Group CE Stephen Saad said the deal is part of the strategy to focus on their core pharmaceutical business in markets that offer scale and alignment to the business model. This is the latest disposal from the company, which is seeking…

Read More